PEDIATRICS Vol. 61 No. 3 March 1978, pp. 491-493
This Article
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lima, J. J.
Right arrow Articles by Jusko, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lima, J. J.
Right arrow Articles by Jusko, W. J.

Fetal Uptake and Neonatal Disposition of Procainamide and Its Acetylated Metabolite: A Case Report

John J. Lima Pharm.D.1, Paul M. Kuritzky M.D.1, Jerome J. Schentag Pharm.D.1, and William J. Jusko Ph.D.1

1 Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital; Departments of Pharmaceutics and Medicine, Schools of Pharmacy and Medicine, State University of New York at Buffalo Buffalo, New York

Few drugs are administered to pregnant women without fear of hazard to the fetus. Because there are few available data on the kinetics and effects of drugs given in pharmacological doses during pregnancy, many are either withheld or given with hesitation. The problem has many origins, not the least important of which are the ethical considerations in studying drug effects and disposition in the fetus and neonate. Measuring urinary drug excretion after birth is one relatively noninvasive method of examining fetal drug uptake and neonatal elimination. We have utilized this approach to examine the disposition of transplacentally acquired procainamide and its active metabolite, N-acetylated procainamide, in the neonate.